Electrophysiological effects of natriuretic peptides in the heart are mediated by multiple receptor subtypes

Progress in Biophysics and Molecular Biology

Volumn 120, Issue 1-3, 2016, Pages 37-49

  Moghtadaei, Motahareh ^a   Polina, Iuliia ^a   Rose, Robert A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Action potentials; Atrial fibrillation; Ion channels; Natriuretic peptide receptors; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR RECEPTOR; NATRIURETIC FACTOR;

AMINO ACID SEQUENCE; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; ELECTROPHYSIOLOGY; HEART; HEART DISEASES; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ELECTROPHYSIOLOGICAL PHENOMENA; HEART; HEART DISEASES; HUMANS; MYOCARDIUM; NATRIURETIC PEPTIDES; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 84951310711     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.12.001     Document Type: Article

References (170)

1. Abraham R.L., Yang T., Blair M., Roden D.M., Darbar D. Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. J. Mol. Cell. Cardiol. 2010, 48:181-190.
2. Ackermann U. Cardiovascular effects of atrial natriuretic extract in the whole animal. Fed. Proc. 1986, 45:2111-2114.
3. Ackermann U., Irizawa T.G., Milojevic S., Sonnenberg H. Cardiovascular effects of atrial extracts in anesthetized rats. Can. J. Physiol. Pharmacol. 1984, 62:819-826.
4. Aflaki M., Qi X.Y., Xiao L., Ordog B., Tadevosyan A., Luo X., Maguy A., Shi Y., Tardif J.C., Nattel S. Exchange protein directly activated by cAMP mediates slow delayed-rectifier current remodeling by sustained beta-adrenergic activation in guinea pig hearts. Circ. Res. 2014, 114:993-1003.
5. Allen D.E., Gellai M. Cardioinhibitory effect of atrial peptide in conscious rats. Am. J. Physiol. 1987, 252:R610-R616.
6. Anand-Srivastava M.B. Natriuretic peptide receptor-C signaling and regulation. Peptides 2005, 26:1044-1059.
7. Anand-Srivastava M.B., Sehl P.D., Lowe D.G. Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein. J. Biol. Chem. 1996, 271:19324-19329.
8. Anand-Srivastava M.B., Trachte G.J. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol. Rev. 1993, 45:455-497.
9. Azer J., Hua R., Krishnaswamy P.S., Rose R.A. Effects of natriuretic peptides on electrical conduction in the sinoatrial node and atrial myocardium of the heart. J. Physiol. 2014, 592:1025-1045.
10. Azer J., Hua R., Vella K., Rose R.A. Natriuretic peptides regulate heart rate and sinoatrial node function by activating multiple natriuretic peptide receptors. J. Mol. Cell. Cardiol. 2012, 53:715-724.
11. Baudino T.A., Carver W., Giles W., Borg T.K. Cardiac fibroblasts: friend or foe?. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1015-H1026.
12. Beaulieu P., Cardinal R., De Lean A., Lambert C. Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs. Br. J. Pharmacol. 1996, 118:1790-1796.
13. Beaulieu P., Cardinal R., Page P., Francoeur F., Tremblay J., Lambert C. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am. J. Physiol. 1997, 273:H1933-H1940.
14. Belluardo P., Cataliotti A., Bonaiuto L., Giuffre E., Maugeri E., Noto P., Orlando G., Raspa G., Piazza B., Babuin L., Chen H.H., Martin F.L., McKie P.M., Heublein D.M., Burnett J.C., Malatino L.S. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H1529-H1535.
15. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
16. Bielmann C., Rignault-Clerc S., Liaudet L., Li F., Kunieda T., Sogawa C., Zehnder T., Waeber B., Feihl F., Rosenblatt-Velin N. Brain natriuretic peptide is able to stimulate cardiac progenitor cell proliferation and differentiation in murine hearts after birth. Basic Res. Cardiol. 2015, 110:455.
17. Biollaz J., Nussberger J., Waeber B., Brunner H.R. Clinical pharmacology of atrial natriuretic (3-28) eicosahexapeptide. J. Hypertens. Suppl. 1986, 4:S101-S108.
18. Bishu K., Hamdani N., Mohammed S.F., Kruger M., Ohtani T., Ogut O., Brozovich F.V., Burnett J.C., Linke W.A., Redfield M.M. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 2011, 124:2882-2891.
19. + current in fetal single ventricular cells. J. Mol. Cell. Cardiol. 1993, 25:1305-1316.
20. Boerrigter G., Costello-Boerrigter L.C., Burnett J.C. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin. 2009, 5:501-514.
21. 2+ current in human atrial myocytes. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H764-H773.
22. Boixel C., Gonzalez W., Louedec L., Hatem S.N. Mechanisms of L-type Ca(2+) current downregulation in rat atrial myocytes during heart failure. Circ. Res. 2001, 89:607-613.
23. Bouman L.N., Gerlings E.D., Biersteker P.A., Bonke F.I. Pacemaker shift in the sino-atrial node during vagal stimulation. Pflugers Arch. 1968, 302:255-267.
24. Brilla C.G., Maisch B. Regulation of the structural remodelling of the myocardium: from hypertrophy to heart failure. Eur. Heart J. 1994, 15(Suppl. D):45-52.
25. Brilla C.G., Maisch B., Zhou G., Weber K.T. Hormonal regulation of cardiac fibroblast function. Eur. Heart J. 1995, 16(Suppl. C):45-50.
26. Burley D.S., Cox C.D., Zhang J., Wann K.T., Baxter G.F. Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res. Cardiol. 2014, 109:402.
27. Burnett J.C., Kao P.C., Hu D.C., Heser D.W., Heublein D., Granger J.P., Opgenorth T.J., Reeder G.S. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986, 231:1145-1147.
28. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 2008, 51:802-809.
29. Bussien J.P., Biollaz J., Waeber B., Nussberger J., Turini G.A., Brunner H.R., Brunner-Ferber F., Gomez H.J., Otterbein E.S. Dose-dependent effect of atrial natriuretic peptide on blood pressure, heart rate, and skin blood flow of normal volunteers. J. Cardiovasc Pharmacol. 1986, 8:216-220.
30. Cao L., Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995, 25:227-234.
31. Castro L.R., Verde I., Cooper D.M., Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006, 113:2221-2228.
32. Chatelier A., Mercier A., Tremblier B., Theriault O., Moubarak M., Benamer N., Corbi P., Bois P., Chahine M., Faivre J.F. A distinct de novo expression of Nav1.5 sodium channels in human atrial fibroblasts differentiated into myofibroblasts. J. Physiol. 2012, 590:4307-4319.
33. Chen H.H., Burnett J.C. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J. Cardiovasc Pharmacol. 1998, 32(Suppl. 3):S22-S28.
34. Chilton L., Giles W.R., Smith G.L. Evidence of intercellular coupling between co-cultured adult rabbit ventricular myocytes and myofibroblasts. J. Physiol. 2007, 583:225-236.
35. Chilton L., Ohya S., Freed D., George E., Drobic V., Shibukawa Y., Maccannell K.A., Imaizumi Y., Clark R.B., Dixon I.M., Giles W.R. K+ currents regulate the resting membrane potential, proliferation, and contractile responses in ventricular fibroblasts and myofibroblasts. Am. J. Physiol. Heart Circ. Physiol. 2005, 288:H2931-H2939.
36. Clapham D.E. TRP channels as cellular sensors. Nature 2003, 426:517-524.
37. Clapham D.E., Runnels L.W., Strubing C. The TRP ion channel family. Nat. Rev. Neurosci. 2001, 2:387-396.
38. Clemo H.F., Baumgarten C.M., Ellenbogen K.A., Stambler B.S. Atrial natriuretic peptide and cardiac electrophysiology: autonomic and direct effects. J. Cardiovasc. Electrophysiol. 1996, 7:149-162.
39. Crozier I., Richards A.M., Foy S.G., Ikram H. Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction system in man. Pacing Clin. Electrophysiol. 1993, 16:738-742.
40. Cui J., Melman Y., Palma E., Fishman G.I., McDonald T.V. Cyclic AMP regulates the HERG K(+) channel by dual pathways. Curr. Biol. 2000, 10:671-674.
41. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981, 28:89-94.
42. Dickey D.M., Flora D.R., Bryan P.M., Xu X., Chen Y., Potter L.R. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007, 148:3518-3522.
43. Dickey D.M., Potter L.R. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J. Mol. Cell. Cardiol. 2011, 51:67-71.
44. Dickey D.M., Yoder A.R., Potter L.R. A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J. Biol. Chem. 2009, 284:19196-19202.
45. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu. Rev. Physiol. 1993, 55:455-472.
46. Ding W.G., Toyoda F., Matsuura H. Blocking action of chromanol 293B on the slow component of delayed rectifier K(+) current in guinea-pig sino-atrial node cells. Br. J. Pharmacol. 2002, 137:253-262.
47. Doyle D.D., Upshaw-Earley J., Bell E.L., Palfrey H.C. Natriuretic peptide receptor-B in adult rat ventricle is predominantly confined to the nonmyocyte population. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H2117-H2123.
48. 2+ signals confer fibrogenesis in human atrial fibrillation. Circ. Res. 2010, 106:992-1003.
49. Edwards B.S., Zimmerman R.S., Schwab T.R., Heublein D.M., Burnett J.C. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ. Res. 1988, 62:191-195.
50. Egom E.E., Vella K., Hua R., Jansen H.J., Moghtadaei M., Polina I., Bogachev O., Hurnik R., Mackasey M., Rafferty S., Ray G., Rose R.A. Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C. J. Physiol. 2015, 593:1127-1146.
51. Fedorov V.V., Hucker W.J., Dobrzynski H., Rosenshtraukh L.V., Efimov I.R. Postganglionic nerve stimulation induces temporal inhibition of excitability in rabbit sinoatrial node. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H612-H623.
52. Feil R., Lohmann S.M., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ. Res. 2003, 93:907-916.
53. Flynn T.G., de Bold M.L., de Bold A.J. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem. Biophys. Res. Commun. 1983, 117:859-865.
54. Franco-Saenz R., Somani P., Mulrow P.J. Bradycardia after infusion of atrial natriuretic factor. Ann. Intern. Med. 1987, 107:594.
55. Friedewald V.E., Burnett J.C., Januzzi J.L., Roberts W.C., Yancy C.W. The editor's roundtable: B-type natriuretic peptide. Am. J. Cardiol. 2008, 101:1733-1740.
56. Gisbert M.P., Fischmeister R. Atrial natriuretic factor regulates the calcium current in frog isolated cardiac cells. Circ. Res. 1988, 62:660-667.
57. Glukhov A.V., Fedorov V.V., Anderson M.E., Mohler P.J., Efimov I.R. Functional anatomy of the murine sinus node: high-resolution optical mapping of ankyrin-B heterozygous mice. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H482-H491.
58. Goetz K.L., Wang B.C., Geer P.G., Sundet W.D., Needleman P. Effects of atriopeptin infusion versus effects of left atrial stretch in awake dogs. Am. J. Physiol. 1986, 250:R221-R226.
59. Gollob M.H., Jones D.L., Krahn A.D., Danis L., Gong X.Q., Shao Q., Liu X., Veinot J.P., Tang A.S., Stewart A.F., Tesson F., Klein G.J., Yee R., Skanes A.C., Guiraudon G.M., Ebihara L., Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med. 2006, 354:2677-2688.
60. Guellich A., Mehel H., Fischmeister R. Cyclic AMP synthesis and hydrolysis in the normal and failing heart. Pflugers Arch. 2014, 466:1163-1175.
61. Harada E., Nakagawa O., Yoshimura M., Harada M., Nakagawa M., Mizuno Y., Shimasaki Y., Nakayama M., Yasue H., Kuwahara K., Saito Y., Nakao K. Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J. Mol. Cell. Cardiol. 1999, 31:1997-2006.
62. Harada M., Luo X., Qi X.Y., Tadevosyan A., Maguy A., Ordog B., Ledoux J., Kato T., Naud P., Voigt N., Shi Y., Kamiya K., Murohara T., Kodama I., Tardif J.C., Schotten U., Van Wagoner D.R., Dobrev D., Nattel S. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 2012, 126:2051-2064.
63. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17442-17447.
64. Hirata Y., Ishii M., Sugimoto T., Matsuoka H., Sugimoto T., Kangawa K., Matsuo H. The effects of human atrial 28-amino acid peptide on systemic and renal hemodynamics in anesthetized rats. Circ. Res. 1985, 57:634-639.
65. Hodgson-Zingman D.M., Karst M.L., Zingman L.V., Heublein D.M., Darbar D., Herron K.J., Ballew J.D., de Andrade M., Burnett J.C., Olson T.M. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N. Engl. J. Med. 2008, 359:158-165.
66. Hofmann T., Obukhov A.G., Schaefer M., Harteneck C., Gudermann T., Schultz G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999, 397:259-263.
67. Horio T., Tokudome T., Maki T., Yoshihara F., Suga S., Nishikimi T., Kojima M., Kawano Y., Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 2003, 144:2279-2284.
68. Hua R., Adamczyk A., Robbins C., Ray G., Rose R.A. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium. PLoS One 2012, 7:e47652.
69. Hua R., MacLeod S.L., Polina I., Moghtadaei M., Jansen H.J., Bogachev O., O'Blenes S.B., Sapp J.L., Legare J.F., Rose R.A. Effects of wild-type and mutant forms of atrial natriuretic peptide on atrial electrophysiology and arrhythmogenesis. Circ. Arrhythm. Electrophysiol. 2015, 8:1240-1254.
70. Huntley B.K., Ichiki T., Sangaralingham S.J., Chen H.H., Burnett J.C. B-type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts. J. Cell. Physiol. 2010, 225:251-255.
71. Huntley B.K., Sandberg S.M., Noser J.A., Cataliotti A., Redfield M.M., Matsuda Y., Burnett J.C. BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors. J. Cell. Physiol. 2006, 209:943-949.
72. Irisawa H., Brown H.F., Giles W. Cardiac pacemaking in the sinoatrial node. Physiol. Rev. 1993, 73:197-227.
73. Jansen H.J., Rose R.A. Natriuretic peptides: critical regulators of cardiac fibroblasts and the extracellular matrix in the heart. Cardiac Fibrosis and Heart Failure: Cause or Effect 2015, 383-404. Springer International Publishing. I.M. Dixon, J.T. Wigle (Eds.).
74. Kecskemeti V., Pacher P., Pankucsi C., Nanasi P. Comparative study of cardiac electrophysiological effects of atrial natriuretic peptide. Mol. Cell. Biochem. 1996, 160-161:53-59.
75. Kiehn J., Karle C., Thomas D., Yao X., Brachmann J., Kubler W. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J. Biol. Chem. 1998, 273:25285-25291.
76. Kleinert H.D., Volpe M., Odell G., Marion D., Atlas S.A., Camargo M.J., Laragh J.H., Maack T. Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs. Hypertension 1986, 8:312-316.
77. Kohl P. Heterogeneous cell coupling in the heart: an electrophysiological role for fibroblasts. Circ. Res. 2003, 93:381-383.
78. Kohl P., Camelliti P., Burton F.L., Smith G.L. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J. Electrocardiol. 2005, 38:45-50.
79. Koyama S., Nishida Y., Hosomi H., Abe Y. Participation of baroreceptor reflexes in blood pressure and sympathetic nerve responses to a synthetic human atrial natriuretic peptide in anesthetized dogs. Eur. J. Pharmacol. 1986, 127:43-48.
80. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res. Cardiol. 2004, 99:76-82.
81. 2+ clocks and surface membrane voltage clocks controls the timekeeping mechanism of the heart's pacemaker. Circ. Res. 2010, 106:659-673.
82. Lambert C., Ribuot C., Robichaud A., Cusson J.R. Negative chronotropic effect of the atrial natriuretic peptide in an anesthetized dog model. Eur. J. Pharmacol. 1994, 252:245-252.
83. + current in human atrial cells. Pflugers Arch. 1992, 421:486-491.
84. Lee D.I., Zhu G., Sasaki T., Cho G.S., Hamdani N., Holewinski R., Jo S.H., Danner T., Zhang M., Rainer P.P., Bedja D., Kirk J.A., Ranek M.J., Dostmann W.R., Kwon C., Margulies K.B., Van Eyk J.E., Paulus W.J., Takimoto E., Kass D.A. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 2015, 519:472-476.
85. Lei M., Jones S.A., Liu J., Lancaster M.K., Fung S.S., Dobrzynski H., Camelliti P., Maier S.K., Noble D., Boyett M.R. Requirement of neuronal- and cardiac-type sodium channels for murine sinoatrial node pacemaking. J. Physiol. 2004, 559:835-848.
86. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med. 1998, 339:321-328.
87. Li G.R., Feng J., Wang Z., Fermini B., Nattel S. Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ. Res. 1996, 78:903-915.
88. Lisy O., Huntley B.K., McCormick D.J., Kurlansky P.A., Burnett J.C. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J. Am. Coll. Cardiol. 2008, 52:60-68.
89. Lisy O., Lainchbury J.G., Leskinen H., Burnett J.C. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension 2001, 37:1089-1094.
90. Lohmann S.M., Fischmeister R., Walter U. Signal transduction by cGMP in heart. Basic Res. Cardiol. 1991, 86:503-514.
91. Lohmann S.M., Vaandrager A.B., Smolenski A., Walter U., De Jonge H.R. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem. Sci. 1997, 22:307-312.
92. Lonardo G., Cerbai E., Casini S., Giunti G., Bonacchi M., Battaglia F., Fiorani B., Stefano P.L., Sani G., Mugelli A. Atrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytes. Cardiovasc Res. 2004, 63:528-536.
93. Lopez M.J., Wong S.K., Kishimoto I., Dubois S., Mach V., Friesen J., Garbers D.L., Beuve A. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995, 378:65-68.
94. Lu T., Lee H.C., Kabat J.A., Shibata E.F. Modulation of rat cardiac sodium channel by the stimulatory G protein alpha subunit. J. Physiol. 1999, 518(Pt 2):371-384.
95. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 2000, 52:375-414.
96. Maack T., Suzuki M., Almeida F.A., Nussenzveig D., Scarborough R.M., McEnroe G.A., Lewicki J.A. Physiological role of silent receptors of atrial natriuretic factor. Science 1987, 238:675-678.
97. Macheret F., Heublein D., Costello-Boerrigter L.C., Boerrigter G., McKie P., Bellavia D., Mangiafico S., Ikeda Y., Bailey K., Scott C.G., Sandberg S., Chen H.H., Malatino L., Redfield M.M., Rodeheffer R., Burnett J., Cataliotti A. Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J. Am. Coll. Cardiol. 2012, 60:1558-1565.
98. Mangiafico S., Costello-Boerrigter L.C., Andersen I.A., Cataliotti A., Burnett J.C. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur. Heart J. 2013, 34:886-893.
99. Mangoni M.E., Nargeot J. Genesis and regulation of the heart automaticity. Physiol. Rev. 2008, 88:919-982.
100. Matsuda J.J., Lee H., Shibata E.F. Enhancement of rabbit cardiac sodium channels by beta-adrenergic stimulation. Circ. Res. 1992, 70:199-207.
101. Matsukawa N., Grzesik W.J., Takahashi N., Pandey K.N., Pang S., Yamauchi M., Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:7403-7408.
102. Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J., Raymond D.R., Elbatarny H.S., Jimmo S.L. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 2003, 64:533-546.
103. Mery P.F., Lohmann S.M., Walter U., Fischmeister R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:1197-1201.
104. Miao L., Wang M., Yin W.X., Yuan Q., Chen Y.X., Fleischmann B., Hescheler J., Ji G. Atrial natriuretic peptide regulates Ca channel in early developmental cardiomyocytes. PLoS One 2010, 5:e8847.
105. Miller W.L., Phelps M.A., Wood C.M., Schellenberger U., Van Le A., Perichon R., Jaffe A.S. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ. Heart Fail. 2011, 4:355-360.
106. Moltzau L.R., Aronsen J.M., Meier S., Skogestad J., Orstavik O., Lothe G.B., Sjaastad I., Skomedal T., Osnes J.B., Levy F.O., Qvigstad E. Different compartmentation of responses to brain natriuretic peptide and C-type natriuretic peptide in failing rat ventricle. J. Pharmacol. Exp. Ther. 2014, 350:681-690.
107. Moltzau L.R., Meier S., Aronsen J.M., Afzal F., Sjaastad I., Skomedal T., Osnes J.B., Levy F.O., Qvigstad E. Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium. Naunyn Schmiedeb. Arch. Pharmacol. 2014, 387:407-417.
108. Murakawa Y., Yamashita T., Kanese Y., Omata M. Effect of atrial natriuretic peptide on electrical defibrillation efficacy. J. Cardiovasc. Electrophysiol. 1998, 9:962-969.
109. Murthy K.S., Teng B.Q., Zhou H., Jin J.G., Grider J.R., Makhlouf G.M. G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278:G974-G980.
110. Nakao K., Ogawa Y., Suga S., Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: natriuretic peptide receptors. J. Hypertens. 1992, 10:1111-1114.
111. Nicholls M.G., Richards A.M. Human studies with atrial natriuretic factor. Endocrinol. Metab. Clin. North Am. 1987, 16:199-223.
112. Niederkofler E.E., Kiernan U.A., O'Rear J., Menon S., Saghir S., Protter A.A., Nelson R.W., Schellenberger U. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 2008, 1:258-264.
113. Nishikimi T., Kuwahara K., Nakagawa Y., Kangawa K., Minamino N., Nakao K. Complexity of molecular forms of B-type natriuretic peptide in heart failure. Heart 2013, 99:677-679.
114. Nojiri T., Yamamoto K., Maeda H., Takeuchi Y., Funakoshi Y., Inoue M., Okumura M. Effect of low-dose human atrial natriuretic peptide on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer: a double-blind, placebo-controlled study. J. Thorac. Cardiovasc. Surg. 2012, 143:488-494.
115. Nunez D.J., Dickson M.C., Brown M.J. Natriuretic peptide receptor mRNAs in the rat and human heart. J. Clin. Invest. 1992, 90:1966-1971.
116. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.S., Reddick R.L., Pandey K.N., Milgram S.L., Smithies O., Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14730-14735.
117. Omori K., Kotera J. Overview of PDEs and their regulation. Circ. Res. 2007, 100:309-327.
118. 2+ current in guinea-pig ventricular cells. J. Physiol. 1991, 443:387-404.
119. Pagano M., Anand-Srivastava M.B. Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity. J. Biol. Chem. 2001, 276:22064-22070.
120. 2+ channel activity by the phosphorylation of alpha1c proteins. Exp. Mol. Med. 2012, 44:363-368.
121. Perrin M.J., Gollob M.H. The role of atrial natriuretic peptide in modulating cardiac electrophysiology. Heart Rhythm 2012, 9:610-615.
122. Potter L.R., Abbey-Hosch S., Dickey D.M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 2006, 27:47-72.
123. Qvigstad E., Moltzau L.R., Aronsen J.M., Nguyen C.H., Hougen K., Sjaastad I., Levy F.O., Skomedal T., Osnes J.B. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res. 2010, 85:763-772.
124. Redondo J., Bishop J.E., Wilkins M.R. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br. J. Pharmacol. 1998, 124:1455-1462.
125. Richards A.M. The natriuretic peptides in heart failure. Basic Res. Cardiol. 2004, 99:94-100.
126. Rivet-Bastide M., Vandecasteele G., Hatem S., Verde I., Benardeau A., Mercadier J.J., Fischmeister R. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J. Clin. Invest. 1997, 99:2710-2718.
127. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias?. Heart Rhythm 2009, 6:848-856.
128. Rose R.A. CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Curr. Opin. Investig. Drugs 2010, 11:349-356.
129. 2+ entry through TRP-C channels regulates fibroblast biology in chronic atrial fibrillation. Circulation 2012, 126:2039-2041.
130. Rose R.A., Giles W.R. Natriuretic peptide C receptor signalling in the heart and vasculature. J. Physiol. 2008, 586:353-366.
131. Rose R.A., Hatano N., Ohya S., Imaizumi Y., Giles W.R. C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling. J. Physiol. 2007, 580:255-274.
132. 2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2454-H2462.
133. Rose R.A., Lomax A.E., Kondo C.S., Anand-Srivastava M.B., Giles W.R. Effects of C-type natriuretic peptide on ionic currents in mouse sinoatrial node: a role for the NPR-C receptor. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H1970-H1977.
134. Rozmaritsa N., Christ T., Van Wagoner D.R., Haase H., Stasch J.P., Matschke K., Ravens U. Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation. Cardiovasc Res. 2014, 101:533-542.
135. Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg P.W., Burnett J.C. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin. Proc. 1999, 74:126-130.
136. Schindler R.F.R., Brand T. The Popeye domain containing protein family - a novel class of camp effectors with important functions in multiple tissues. Prog. Biophys. Mol. Biol. 2016, 120(1-3):28-36.
137. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J. Biol. Chem. 1992, 267:13928-13932.
138. Sezai A., Hata M., Wakui S., Niino T., Takayama T., Hirayama A., Saito S., Minami K. Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome. Circ. J. 2007, 71:1401-1407.
139. Sezai A., Iida M., Yoshitake I., Wakui S., Osaka S., Kimura H., Yaoita H., Hata H., Shiono M., Nakai T., Takayama T., Kunimoto S., Kasamaki Y., Hirayama A. Carperitide and atrial fibrillation after coronary bypass grafting: The Nihon University Working Group Study of low-dose HANP infusion therapy during cardiac surgery trial for postoperative atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2015, 8:546-553.
140. Shibukawa Y., Chilton E.L., Maccannell K.A., Clark R.B., Giles W.R. K+ currents activated by depolarization in cardiac fibroblasts. Biophys. J. 2005, 88:3924-3935.
141. Shimizu K., Shintani Y., Ding W.G., Matsuura H., Bamba T. Potentiation of slow component of delayed rectifier K(+) current by cGMP via two distinct mechanisms: inhibition of phosphodiesterase 3 and activation of protein kinase G. Br. J. Pharmacol. 2002, 137:127-137.
142. Sodi R., Dubuis E., Shenkin A., Hart G. B-type natriuretic peptide (BNP) attenuates the L-type calcium current and regulates ventricular myocyte function. Regul. Pept. 2008, 151:95-105.
143. Sorbera L.A., Morad M. Atrionatriuretic peptide transforms cardiac sodium channels into calcium-conducting channels. Science 1990, 247:969-973.
144. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105:1164-1176.
145. Springer J., Azer J., Hua R., Robbins C., Adamczyk A., McBoyle S., Bissell M.B., Rose R.A. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J. Mol. Cell. Cardiol. 2012, 52:1122-1134.
146. Stambler B.S., Guo G.B. Atrial natriuretic peptide has dose-dependent, autonomically mediated effects on atrial refractoriness and repolarization in anesthetized dogs. J. Cardiovasc Electrophysiol. 2005, 16:1341-1347.
147. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
148. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem. Biophys. Res. Commun. 1990, 168:863-870.
149. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., Kasahara M., Hashimoto R., Katsuura G., Mukoyama M., Itoh H., Saito Y., Tanaka I., Otani H., Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:4239-4244.
150. 2+ channel activity by human natriuretic peptide in rabbit heart cells. Br. J. Pharmacol. 1995, 114:1076-1082.
151. Tsuruda T., Boerrigter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., Chen H.H., Burnett J.C. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ. Res. 2002, 91:1127-1134.
152. Ripplinger C.M., Noujaim S.F., Linz D. The nervous heart. Prog. Biophys. Mol. Biol. 2016, 120(1-3):199-209.
153. Vandecasteele G., Verde I., Rucker-Martin C., Donzeau-Gouge P., Fischmeister R. Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J. Physiol. 2001, 533:329-340.
154. 2+ releases. Circ. Res. 2008, 102:761-769.
155. Vollmar A.M., Gerbes A.L., Nemer M., Schulz R. Detection of C-type natriuretic peptide (CNP) transcript in the rat heart and immune organs. Endocrinology 1993, 132:1872-1874.
156. Volpe M., Lembo G., Condorelli G., De Luca N., Lamenza F., Indolfi C., Trimarco B. Converting enzyme inhibition prevents the effects of atrial natriuretic factor on baroreflex responses in humans. Circulation 1990, 82:1214-1221.
157. Volpe M., Mele A.F., Indolfi C., De Luca N., Lembo G., Focaccio A., Condorelli M., Trimarco B. Hemodynamic and hormonal effects of atrial natriuretic factor in patients with essential hypertension. J. Am. Coll. Cardiol. 1987, 10:787-793.
158. Wada A., Tsutamoto T., Matsuda Y., Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994, 89:2232-2240.
159. Wang Y., Wagner M.B., Joyner R.W., Kumar R. cGMP-dependent protein kinase mediates stimulation of L-type calcium current by cGMP in rabbit atrial cells. Cardiovasc Res. 2000, 48:310-322.
160. Wei C.M., Heublein D.M., Perrella M.A., Lerman A., Rodeheffer R.J., McGregor C.G., Edwards W.D., Schaff H.V., Burnett J.C. Natriuretic peptide system in human heart failure. Circulation 1993, 88:1004-1009.
161. Weidmann P., Hasler L., Gnadinger M.P., Lang R.E., Uehlinger D.E., Shaw S., Rascher W., Reubi F.C. Blood levels and renal effects of atrial natriuretic peptide in normal man. J. Clin. Invest. 1986, 77:734-742.
162. Wijffels M.C., Kirchhof C.J., Dorland R., Power J., Allessie M.A. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation 1997, 96:3710-3720.
163. Wolf R.M., Glynn P., Hashemi S., Zarei K., Mitchell C.C., Anderson M.E., Mohler P.J., Hund T.J. Atrial fibrillation and sinus node dysfunction in human ankyrin-B syndrome: a computational analysis. Am. J. Physiol. Heart Circ. Physiol. 2013, 304:H1253-H1266.
164. Wright G.A., Struthers A.D. Natriuretic peptides as a prognostic marker and therapeutic target in heart failure. Heart 2006, 92:149-151.
165. Yang J.M., Yang S.N., Lin C.I. The electrophysiological and mechanical effects of atrial natriuretic peptide and acetylcholine on guinea pig ventricular papillary muscle. Proc. Natl. Sci. Counc. Repub. China B 1989, 13:289-297.
166. Yarbrough T.L., Lu T., Lee H.C., Shibata E.F. Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude. Circ. Res. 2002, 90:443-449.
167. Yasuno S., Usami S., Kuwahara K., Nakanishi M., Arai Y., Kinoshita H., Nakagawa Y., Fujiwara M., Murakami M., Ueshima K., Harada M., Nakao K. Endogenous cardiac natriuretic peptides protect the heart in a mouse model of dilated cardiomyopathy and sudden death. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1804-H1810.
168. Zaccolo M., Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 2007, 100:1569-1578.
169. Zhang M., Takimoto E., Lee D.I., Santos C.X., Nakamura T., Hsu S., Jiang A., Nagayama T., Bedja D., Yuan Y., Eaton P., Shah A.M., Kass D.A. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation 2012, 126:942-951.
170. Zhou H., Murthy K.S. Identification of the G protein-activating sequence of the single-transmembrane natriuretic peptide receptor C (NPR-C). Am. J. Physiol. Cell Physiol. 2003, 284:C1255-C1261.